Company
Hong Kong
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
2
2 still marketed
Novel approvals
2
Approvals since 2021
0
Originals and new uses
Phase 3 trials
125
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and/or PolypectomyPivotal-lookingRecruiting
Chinese University of Hong KongAcademic, hospital or other
NCT07052799 · 2,514 participants (planned) · Start Feb 10, 2026 · Primary completion Dec 31, 2030
Drug: Aspirin 80mg; Placebo Oral Tablet · For: Myocardial Infarction (MI); Cardiovascular Events; Post Polypectomy Bleeding in Antiplatelet Patients
Sites: Hong Kong, Hong Kong
- Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP PancreatitisPivotal-lookingRecruiting
Chinese University of Hong KongAcademic, hospital or other
NCT03713879 · 1,734 participants (planned) · Start Mar 21, 2019 · Primary completion May 31, 2028
Drug: Indomethacin · For: Post ERCP Pancreatitis
Sites: Xi'an, China; Shanghai, China; Tianjin, China · 7 sites in all
- PREDICATE Trial For Respiratory Tract InfectionsPivotal-lookingRecruiting
The University of Hong KongAcademic, hospital or other
NCT06472219 · 1,300 participants (planned) · Start Dec 23, 2024 · Primary completion Dec 8, 2027
Drug: Prednisolone 30 mg; Placebo · For: Respiratory Tract Infections
Sites: Hong Kong, Hong Kong
- Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency ContraceptionPivotal-lookingRecruiting
The University of Hong KongAcademic, hospital or other
NCT06727734 · 980 participants (planned) · Start Jan 18, 2025 · Primary completion Sep 2027
Drug: Levonorgestrel; Piroxicam and 4 more · For: Contraception
Sites: Hong Kong, Hong Kong
- GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FETPivotal-lookingRecruiting
The University of Hong KongAcademic, hospital or other
NCT04064840 · 784 participants (planned) · Start Sep 1, 2019 · Primary completion Sep 1, 2024
Drug: IVF: Decapeptyl and hCG; FET: Decapeptyl and 2 more · For: Subfertility
Sites: Hong Kong, China
- Oral Dydrogesterone as Luteal Phase Support in Natural Cycle FETPivotal-lookingRecruiting
The University of Hong KongAcademic, hospital or other
NCT03859921 · 716 participants (planned) · Start Jul 1, 2021 · Primary completion Dec 30, 2025
Drug: Dydrogesterone; Placebo · For: Subfertility
Sites: Hong Kong, China
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)Pivotal-lookingRecruiting
InSilico Medicine Hong Kong LimitedIndustry
NCT07687459 · 320 participants (planned) · Start Sep 9, 2026 · Primary completion Oct 30, 2029
Drug: INS018_055 tablets; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Hefei, China; Beijing, China; Fuzhou, China · 47 sites in all
- Analgesic Efficacy of Different Liposomal Bupivacaine Doses in the Adductor Canal Block for Total Knee ArthroplastyPivotal-lookingRecruiting
The University of Hong KongAcademic, hospital or other
NCT06740214 · 177 participants (planned) · Start Sep 4, 2025 · Primary completion Jun 30, 2027
Drug: 0.5% standard bupivacaine only; 1.33% liposomal bupivacaine with 0.5% standard bupivacaine and 1 more · For: Pain, Postoperative; Analgesic Effect; Total Knee Arthroplasty and 2 more
Sites: Hong Kong, Hong Kong
- Intravenous N-acetylcysteine and Oseltamivir Versus Oseltamivir in Adults Hospitalized With Influenza and PneumoniaPivotal-lookingRecruiting
Chinese University of Hong KongAcademic, hospital or other
NCT03900988 · 160 participants (planned) · Start May 8, 2023 · Primary completion Oct 31, 2027
Drug: N-acetyl cysteine; 5% Dextrose · For: Influenza
Sites: Hong Kong, Hong Kong
- Study of Yupingfeng Powder Treating Allergic Rhinitis (AR)Pivotal-lookingRecruiting
Chinese University of Hong KongAcademic, hospital or other
NCT06608017 · 140 participants (planned) · Start Mar 27, 2025 · Primary completion Dec 31, 2026
Drug: Chinese Herbal Medicine granules · For: Allergic Rhinitis
Sites: Shatin, Hong Kong
Marketed drugs (2)
Newest FDA action first.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.